New treatment for rare inherited liver condition not cost-effective, says NICE in draft guidance
Lumasiran, which has been available via the MHRA’s EAMS, was not recommended for primary hyperoxaluria type 1 in NICE draft guidance.
NICE guidelines
Regulatory Alerts, GP info: Cancer, Specialist info: Oncology, Specialist info: Thoracic cancer , Oncology Room
Durvalumab recommended for non-small-cell lung cancer
NICE has recommended durvalumab for the maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation in final draft guidance, which reviewed the additional evidence collected as part of the Cancer Drugs Fund managed access agreement for the treatment.
NICE issues updated draft recommendations on the symptoms and signs of UTI in under 16s
NICE suggests the draft recommendations are unlikely to substantially change practice because the diagnostic pathway remains the same, although some of the symptoms and signs suggesting a UTI have changed.
Zanubrutinib not recommended in draft guidance for Waldenstrom’s macroglobulinaemia
Long-term evidence on the effectiveness of zanubrutinib is not yet available, and the cost-effectiveness estimate is higher than what is normally considered cost-effective, says NICE.
Ibrutinib not recommended for Waldenstrom’s macroglobulinaemia in draft guidance
It is uncertain how much ibrutinib improves how long people live before their condition worsens and how long they live for compared with chemoimmunotherapy.
